{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-053109","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2023-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.601575+00:00","generated_at":"2026-06-10T00:54:43.112919+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Relay Therapeutics reports RLY-4008 data: 35% ORR in FGFR2 fusions; cash runway extended to 2H2026","bullets":["RLY-4008 achieved 35% ORR in FGFR2-fusion tumors (n=26) and 40% ORR in HR+/HER2- breast cancer (n=10); durable responses of ≥6 months in most responders.","In FGFR2-amplified tumors, 24% ORR (8/34) across multiple tumor types; early signals in FGFR2 mutations (3 PRs).","Safety profile consistent with prior data: no Grade 4/5 adverse events; off-target toxicities clinically insignificant.","Pipeline update: plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet by YE 2023; pause RLY-2139 (CDK2 inhibitor) development.","Cash runway extended by ~1 year, now sufficient into 2H2026; CCA commercial readiness paused to focus on tumor-agnostic opportunity."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-053109","json":"https://secwatch.observer/filing/0000950170-23-053109.json","markdown":"https://secwatch.observer/filing/0000950170-23-053109.md","text":"https://secwatch.observer/filing/0000950170-23-053109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023053109/0000950170-23-053109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023053109/rlay-20231012.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T00:54:43.112919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}